Study summary
Adding venetoclax to azacitidine raised response rates but did not lengthen survival in higher-risk MDS
22.2 momedian survival with venetoclax, vs 21.7 months with placebo
What was tested
Venetoclax, a BCL-2 inhibitor pill that transformed treatment of older adults with AML, added to azacitidine, against azacitidine plus placebo, for newly diagnosed higher-risk MDS.
What they found
- Median survival was 22.2 vs 21.7 months (hazard ratio 0.908), missing the main goal.
- Response rates were higher: 76.2% vs 57.7%.
- Subgroup analyses hinted at benefit in people under 75 and those headed for transplant.
What it means
Azacitidine alone stays the standard for higher-risk MDS; venetoclax may still have a role as a bridge to transplant.
Last reviewed 2026-11-15 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.